In general, global efforts are made to design precision therapies to combat PDAC, including therapeutic targets to inhibit tumor-intrinsic pathways such as KRAS, PI3K, AKT, mTOR, JAK/STAT, SHH, NOTCH, and WNT signaling cascades (Chandana et al., 2019). The gene discussed is KRAS; the disease is neoplasm.